8-K
filed October 17, 2025, 7:59 PM ET
ticker RANI
CIK 0001856725
other material
confidence high
sentiment positive
materiality 0.85
Rani raises $60.3M, partners with Chugai on hemophilia drug via RaniPill
Rani Therapeutics Holdings, Inc.
- Private placement: ~$60.3M gross from 42.6M shares and warrants at $0.48/share (institutional) and $0.605 (affiliate).
- Loan amendment: Avenue converts $6M debt into 12.5M shares and warrants on same PIPE terms.
- Collaboration with Chugai: $10M upfront, up to $18M tech transfer, $57M development, $100M sales milestones, plus royalties.
- Samsara and Anomaly get board appointment rights if each holds ≥25% of its PIPE securities.
- Warrants exercisable five years post-stockholder approval; pre-funded warrants exercisable immediately.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
Rani Therapeutics Holdings, Inc. issued 42,633,337 shares of Class A common stock of common stock to institutional and accredited investors, and Mir Imran for $0.48 per share to Institutional Investors; $0.605 per share to Affiliated Investor; aggregate gross proceeds approximately $60.3 million.
- Security
- common stock
- Shares
- 42,633,337 shares of Class A common stock
- Purchaser
- institutional and accredited investors, and Mir Imran
- Consideration
- $0.48 per share to Institutional Investors; $0.605 per share to Affiliated Investor; aggregate gross proceeds approximately $60.3 million
Exact text from the filing
of 82,366,667 shares of Class A Common Stock (the “Pre-Funded Warrants”). Pursuant to the Purchase Agreement, the purchase price of the Shares to the Institutional Investors is $0.48 per share; and the Purchase Price of the Shares to the Affiliated Investor is $0.605 per share, which reflects the consolidated closing bid price of our Class A Common Stock on
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Rani Therapeutics Holdings, Inc. issued 12,500,000 Shares (or Pre-Funded Warrants in lieu thereof) of common stock to Avenue Venture Opportunities Fund, L.P. for conversion of $6.0 million of outstanding Loans.
- Security
- common stock
- Shares
- 12,500,000 Shares (or Pre-Funded Warrants in lieu thereof)
- Purchaser
- Avenue Venture Opportunities Fund, L.P.
- Consideration
- conversion of $6.0 million of outstanding Loans
Exact text from the filing
On October 16, 2025, the Company, Rani LLC and Avenue entered into an amendment to the Loan Agreement (the “LSA Amendment”), effective as of September 30, 2025, pursuant to which Avenue agreed to convert $6.0 million of outstanding Loans into 12,500,000 Shares (or Pre-Funded Warrants in lieu thereof) in connection with the Private Placement and will receive Warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof), on the same terms as the Purchasers.
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
Rani Therapeutics Holdings, Inc. issued pre-funded warrants to purchase up to an aggregate of 82,366,667 shares of Class A Common Stock of warrant to institutional and accredited investors, and Mir Imran for $0.4799 per Pre-Funded Warrant.
- Security
- warrant
- Shares
- pre-funded warrants to purchase up to an aggregate of 82,366,667 shares of Class A Common Stock
- Purchaser
- institutional and accredited investors, and Mir Imran
- Consideration
- $0.4799 per Pre-Funded Warrant
Exact text from the filing
of 82,366,667 shares of Class A Common Stock (the “Pre-Funded Warrants”). Pursuant to the Purchase Agreement, the purchase price of the Shares to the Institutional Investors is $0.48 per share; and the Purchase Price of the Shares to the Affiliated Investor is $0.605 per share, which reflects the consolidated closing bid price of our Class A Common Stock on
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
Rani Therapeutics Holdings, Inc. issued warrants to purchase up to an aggregate of 125,000,004 shares of Class A Common Stock of warrant to institutional and accredited investors, and Mir Imran for Part of purchase price per share and Common Warrant; exercise price $0.48 per share.
- Security
- warrant
- Shares
- warrants to purchase up to an aggregate of 125,000,004 shares of Class A Common Stock
- Purchaser
- institutional and accredited investors, and Mir Imran
- Consideration
- Part of purchase price per share and Common Warrant; exercise price $0.48 per share
Exact text from the filing
of 82,366,667 shares of Class A Common Stock (the “Pre-Funded Warrants”). Pursuant to the Purchase Agreement, the purchase price of the Shares to the Institutional Investors is $0.48 per share; and the Purchase Price of the Shares to the Affiliated Investor is $0.605 per share, which reflects the consolidated closing bid price of our Class A Common Stock on
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.95
Rani Therapeutics Holdings, Inc. issued Warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof) of warrant to Avenue Venture Opportunities Fund, L.P. for part of conversion of $6.0 million of outstanding Loans.
- Security
- warrant
- Shares
- Warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof)
- Purchaser
- Avenue Venture Opportunities Fund, L.P.
- Consideration
- part of conversion of $6.0 million of outstanding Loans
Exact text from the filing
On October 16, 2025, the Company, Rani LLC and Avenue entered into an amendment to the Loan Agreement (the “LSA Amendment”), effective as of September 30, 2025, pursuant to which Avenue agreed to convert $6.0 million of outstanding Loans into 12,500,000 Shares (or Pre-Funded Warrants in lieu thereof) in connection with the Private Placement and will receive Warrants to purchase up to 12,500,000 shares of Class A Common Stock (or Pre-Funded Warrants in lieu thereof), on the same terms as the Purchasers.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.